Concepts (277)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 65 | 2023 | 563 | 6.750 |
Why?
|
| Lung | 17 | 2023 | 819 | 1.410 |
Why?
|
| Respiratory Function Tests | 16 | 2021 | 165 | 1.130 |
Why?
|
| Pulmonary Emphysema | 10 | 2018 | 86 | 0.980 |
Why?
|
| Asthma | 6 | 2023 | 416 | 0.890 |
Why?
|
| Exercise Tolerance | 13 | 2016 | 68 | 0.870 |
Why?
|
| Smoking | 16 | 2018 | 829 | 0.860 |
Why?
|
| Biomarkers | 13 | 2020 | 1199 | 0.850 |
Why?
|
| Exercise Test | 10 | 2015 | 232 | 0.830 |
Why?
|
| Forced Expiratory Volume | 16 | 2020 | 147 | 0.750 |
Why?
|
| Aged | 54 | 2023 | 13215 | 0.700 |
Why?
|
| Quality of Life | 12 | 2023 | 1102 | 0.680 |
Why?
|
| Spirometry | 10 | 2022 | 93 | 0.670 |
Why?
|
| Metabolomics | 1 | 2019 | 50 | 0.660 |
Why?
|
| Severity of Illness Index | 15 | 2018 | 1441 | 0.660 |
Why?
|
| Energy Metabolism | 1 | 2019 | 344 | 0.560 |
Why?
|
| Middle Aged | 48 | 2021 | 16127 | 0.550 |
Why?
|
| Male | 60 | 2021 | 27275 | 0.530 |
Why?
|
| Cytokines | 2 | 2012 | 903 | 0.520 |
Why?
|
| Female | 61 | 2021 | 30564 | 0.500 |
Why?
|
| Cohort Studies | 17 | 2021 | 2428 | 0.500 |
Why?
|
| Walking | 8 | 2015 | 229 | 0.490 |
Why?
|
| Humans | 78 | 2023 | 58855 | 0.480 |
Why?
|
| Hospitalization | 9 | 2023 | 1270 | 0.480 |
Why?
|
| Pulmonary Diffusing Capacity | 3 | 2021 | 11 | 0.450 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2012 | 58 | 0.430 |
Why?
|
| Lung Diseases, Obstructive | 2 | 2014 | 20 | 0.410 |
Why?
|
| Prospective Studies | 16 | 2019 | 3074 | 0.390 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2012 | 201 | 0.390 |
Why?
|
| Exercise Therapy | 1 | 2012 | 97 | 0.380 |
Why?
|
| Genome-Wide Association Study | 3 | 2018 | 320 | 0.370 |
Why?
|
| Medicare | 5 | 2023 | 601 | 0.370 |
Why?
|
| Lung Neoplasms | 3 | 2023 | 542 | 0.360 |
Why?
|
| Carbon Monoxide | 3 | 2021 | 59 | 0.340 |
Why?
|
| ADAM Proteins | 2 | 2020 | 34 | 0.330 |
Why?
|
| Disease Progression | 11 | 2019 | 1030 | 0.330 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2018 | 670 | 0.330 |
Why?
|
| Respiratory Therapy | 2 | 2018 | 9 | 0.310 |
Why?
|
| Nebulizers and Vaporizers | 2 | 2018 | 31 | 0.310 |
Why?
|
| Body Mass Index | 10 | 2018 | 890 | 0.300 |
Why?
|
| Lung Diseases, Interstitial | 2 | 2023 | 95 | 0.290 |
Why?
|
| Comorbidity | 8 | 2022 | 1083 | 0.280 |
Why?
|
| Predictive Value of Tests | 6 | 2019 | 1020 | 0.280 |
Why?
|
| Hand Strength | 3 | 2015 | 27 | 0.280 |
Why?
|
| Interleukin-6 | 4 | 2013 | 307 | 0.270 |
Why?
|
| Exome | 2 | 2016 | 72 | 0.260 |
Why?
|
| Adult | 23 | 2023 | 15602 | 0.260 |
Why?
|
| Pneumonia | 2 | 2021 | 263 | 0.250 |
Why?
|
| Epithelial Cells | 2 | 2020 | 374 | 0.240 |
Why?
|
| Proteomics | 1 | 2006 | 252 | 0.240 |
Why?
|
| Smokers | 3 | 2021 | 108 | 0.240 |
Why?
|
| Chemokines, CC | 3 | 2013 | 27 | 0.230 |
Why?
|
| Uteroglobin | 2 | 2015 | 7 | 0.230 |
Why?
|
| Early Detection of Cancer | 3 | 2023 | 260 | 0.230 |
Why?
|
| Oxygen Consumption | 3 | 2011 | 196 | 0.220 |
Why?
|
| Membrane Proteins | 2 | 2020 | 839 | 0.220 |
Why?
|
| Vascular Calcification | 2 | 2021 | 19 | 0.220 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2021 | 1446 | 0.220 |
Why?
|
| Survival Rate | 4 | 2019 | 783 | 0.210 |
Why?
|
| Patient Preference | 1 | 2023 | 74 | 0.210 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2018 | 737 | 0.210 |
Why?
|
| Risk Assessment | 5 | 2021 | 1893 | 0.210 |
Why?
|
| Prognosis | 9 | 2015 | 1561 | 0.210 |
Why?
|
| Beclomethasone | 1 | 2022 | 1 | 0.200 |
Why?
|
| Macrophages, Alveolar | 2 | 2020 | 59 | 0.200 |
Why?
|
| Vital Capacity | 7 | 2020 | 72 | 0.200 |
Why?
|
| Pneumonectomy | 3 | 2015 | 78 | 0.200 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2022 | 30 | 0.200 |
Why?
|
| Interleukin-8 | 3 | 2012 | 84 | 0.190 |
Why?
|
| Case-Control Studies | 7 | 2020 | 1048 | 0.190 |
Why?
|
| Risk Factors | 11 | 2022 | 4975 | 0.180 |
Why?
|
| Patient Readmission | 2 | 2023 | 416 | 0.180 |
Why?
|
| Glucocorticoids | 1 | 2022 | 167 | 0.180 |
Why?
|
| Follow-Up Studies | 10 | 2017 | 2316 | 0.180 |
Why?
|
| Bronchi | 1 | 2020 | 75 | 0.170 |
Why?
|
| C-Reactive Protein | 2 | 2013 | 167 | 0.170 |
Why?
|
| United States | 10 | 2023 | 7438 | 0.170 |
Why?
|
| Health Status | 3 | 2015 | 448 | 0.170 |
Why?
|
| Heart Failure | 1 | 2006 | 859 | 0.160 |
Why?
|
| Coronary Artery Disease | 1 | 2021 | 265 | 0.160 |
Why?
|
| Pulmonologists | 1 | 2018 | 3 | 0.160 |
Why?
|
| Survival Analysis | 6 | 2020 | 550 | 0.150 |
Why?
|
| Retrospective Studies | 7 | 2023 | 5922 | 0.150 |
Why?
|
| Aged, 80 and over | 7 | 2021 | 5046 | 0.150 |
Why?
|
| Telemedicine | 1 | 2023 | 327 | 0.150 |
Why?
|
| Eosinophilia | 1 | 2017 | 28 | 0.150 |
Why?
|
| Inflammation | 2 | 2015 | 1096 | 0.150 |
Why?
|
| Endothelium | 1 | 2017 | 20 | 0.140 |
Why?
|
| Antigens, CD | 1 | 2018 | 341 | 0.140 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2012 | 579 | 0.140 |
Why?
|
| Dyspnea | 4 | 2013 | 107 | 0.140 |
Why?
|
| Prevalence | 5 | 2022 | 1277 | 0.140 |
Why?
|
| Genetic Loci | 1 | 2017 | 106 | 0.140 |
Why?
|
| Interleukin-27 | 1 | 2016 | 5 | 0.140 |
Why?
|
| DNA Methylation | 1 | 2018 | 271 | 0.130 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 328 | 0.130 |
Why?
|
| Amyloid beta-Protein Precursor | 2 | 2006 | 71 | 0.130 |
Why?
|
| B-Cell Activating Factor | 1 | 2015 | 9 | 0.130 |
Why?
|
| Lymphoid Tissue | 1 | 2015 | 55 | 0.130 |
Why?
|
| Muscle Weakness | 1 | 2015 | 29 | 0.130 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 646 | 0.130 |
Why?
|
| Disease Management | 1 | 2017 | 219 | 0.130 |
Why?
|
| Interleukin-16 | 2 | 2012 | 24 | 0.130 |
Why?
|
| Spain | 4 | 2018 | 27 | 0.130 |
Why?
|
| Chemokine CCL2 | 2 | 2012 | 54 | 0.130 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 2015 | 4 | 0.130 |
Why?
|
| Information Services | 1 | 2015 | 34 | 0.120 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 2016 | 63 | 0.120 |
Why?
|
| Smoke | 1 | 2015 | 24 | 0.120 |
Why?
|
| Kidney | 1 | 2017 | 391 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 711 | 0.120 |
Why?
|
| Adaptive Immunity | 1 | 2015 | 89 | 0.120 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 413 | 0.120 |
Why?
|
| Oxygen | 1 | 2016 | 301 | 0.120 |
Why?
|
| Matrix Metalloproteinase 8 | 1 | 2014 | 4 | 0.120 |
Why?
|
| Mononuclear Phagocyte System | 1 | 2014 | 3 | 0.120 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 443 | 0.120 |
Why?
|
| Surveys and Questionnaires | 7 | 2022 | 2561 | 0.120 |
Why?
|
| Busulfan | 1 | 2014 | 10 | 0.120 |
Why?
|
| Bronchiolitis Obliterans | 1 | 2014 | 17 | 0.120 |
Why?
|
| Mexican Americans | 1 | 2014 | 19 | 0.110 |
Why?
|
| Transplantation Conditioning | 1 | 2014 | 90 | 0.110 |
Why?
|
| Gene Expression Regulation | 2 | 2018 | 1535 | 0.110 |
Why?
|
| Receptors, Cell Surface | 2 | 2006 | 438 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2016 | 388 | 0.110 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2014 | 141 | 0.110 |
Why?
|
| Proportional Hazards Models | 4 | 2021 | 674 | 0.110 |
Why?
|
| Graft vs Host Disease | 1 | 2014 | 99 | 0.110 |
Why?
|
| Nutrition Surveys | 1 | 2014 | 152 | 0.110 |
Why?
|
| Fibronectins | 1 | 2013 | 43 | 0.110 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2014 | 100 | 0.110 |
Why?
|
| Morbidity | 2 | 2023 | 105 | 0.100 |
Why?
|
| NF-kappa B | 1 | 2015 | 461 | 0.100 |
Why?
|
| B-Lymphocytes | 1 | 2015 | 549 | 0.100 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2012 | 57 | 0.100 |
Why?
|
| Puerto Rico | 2 | 2023 | 224 | 0.100 |
Why?
|
| Longitudinal Studies | 5 | 2014 | 1201 | 0.100 |
Why?
|
| Aging | 1 | 2018 | 720 | 0.100 |
Why?
|
| Time Factors | 6 | 2021 | 3544 | 0.100 |
Why?
|
| Symptom Flare Up | 2 | 2022 | 13 | 0.090 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2014 | 310 | 0.090 |
Why?
|
| Bronchoalveolar Lavage Fluid | 3 | 2015 | 97 | 0.090 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2023 | 151 | 0.090 |
Why?
|
| Bronchoscopy | 2 | 2009 | 63 | 0.090 |
Why?
|
| Regression Analysis | 3 | 2020 | 482 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 820 | 0.090 |
Why?
|
| Sex Characteristics | 1 | 2011 | 198 | 0.080 |
Why?
|
| Stroke Volume | 1 | 2011 | 317 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2020 | 708 | 0.080 |
Why?
|
| Electrocardiography | 2 | 2011 | 521 | 0.070 |
Why?
|
| Blood Gas Analysis | 1 | 2007 | 34 | 0.070 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2007 | 38 | 0.070 |
Why?
|
| ROC Curve | 3 | 2016 | 259 | 0.070 |
Why?
|
| Hydrogels | 1 | 2009 | 105 | 0.070 |
Why?
|
| Postoperative Complications | 1 | 2014 | 1114 | 0.070 |
Why?
|
| Boston | 2 | 2020 | 325 | 0.070 |
Why?
|
| Secretory Leukocyte Peptidase Inhibitor | 1 | 2007 | 1 | 0.070 |
Why?
|
| Leukotriene B4 | 1 | 2007 | 13 | 0.070 |
Why?
|
| Risk | 2 | 2021 | 370 | 0.070 |
Why?
|
| Microarray Analysis | 1 | 2007 | 56 | 0.070 |
Why?
|
| Serpins | 1 | 2006 | 17 | 0.070 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 207 | 0.070 |
Why?
|
| Mice | 6 | 2018 | 10192 | 0.070 |
Why?
|
| Qualitative Research | 2 | 2020 | 595 | 0.070 |
Why?
|
| Multivariate Analysis | 3 | 2014 | 925 | 0.070 |
Why?
|
| Social Class | 2 | 2019 | 123 | 0.070 |
Why?
|
| Genetic Linkage | 1 | 2005 | 101 | 0.060 |
Why?
|
| Linear Models | 1 | 2007 | 418 | 0.060 |
Why?
|
| Phenotype | 2 | 2021 | 1151 | 0.060 |
Why?
|
| Disease Models, Animal | 3 | 2018 | 2042 | 0.060 |
Why?
|
| Animals | 7 | 2018 | 19494 | 0.060 |
Why?
|
| Oxidative Stress | 2 | 2017 | 278 | 0.060 |
Why?
|
| Rest | 2 | 2016 | 43 | 0.060 |
Why?
|
| Africa | 1 | 2023 | 21 | 0.060 |
Why?
|
| Sex Factors | 2 | 2021 | 954 | 0.060 |
Why?
|
| Exercise | 2 | 2020 | 902 | 0.060 |
Why?
|
| Respiratory Muscles | 1 | 2003 | 8 | 0.060 |
Why?
|
| Gene Expression | 1 | 2006 | 804 | 0.050 |
Why?
|
| Mucus | 1 | 2002 | 15 | 0.050 |
Why?
|
| Administration, Inhalation | 1 | 2022 | 109 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2004 | 693 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2017 | 909 | 0.050 |
Why?
|
| Reproducibility of Results | 3 | 2013 | 1537 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2018 | 3158 | 0.050 |
Why?
|
| Uncertainty | 1 | 2020 | 32 | 0.050 |
Why?
|
| Beijing | 1 | 2020 | 1 | 0.050 |
Why?
|
| THP-1 Cells | 1 | 2020 | 17 | 0.050 |
Why?
|
| England | 1 | 2020 | 21 | 0.050 |
Why?
|
| Massachusetts | 1 | 2006 | 2076 | 0.040 |
Why?
|
| Treatment Outcome | 4 | 2015 | 5099 | 0.040 |
Why?
|
| Cough | 1 | 2002 | 181 | 0.040 |
Why?
|
| Hospitals | 1 | 2023 | 373 | 0.040 |
Why?
|
| Apoptosis | 2 | 2015 | 1034 | 0.040 |
Why?
|
| Fee-for-Service Plans | 1 | 2020 | 67 | 0.040 |
Why?
|
| Propensity Score | 1 | 2020 | 130 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 98 | 0.040 |
Why?
|
| Focus Groups | 1 | 2020 | 290 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2020 | 362 | 0.040 |
Why?
|
| Perception | 1 | 2020 | 177 | 0.040 |
Why?
|
| Logistic Models | 2 | 2016 | 1245 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2003 | 668 | 0.040 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 1 | 2018 | 6 | 0.040 |
Why?
|
| Young Adult | 2 | 2020 | 4275 | 0.040 |
Why?
|
| Cigarette Smoking | 1 | 2018 | 52 | 0.040 |
Why?
|
| Quantitative Trait Loci | 1 | 2018 | 71 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2017 | 93 | 0.040 |
Why?
|
| Epigenomics | 1 | 2018 | 54 | 0.040 |
Why?
|
| Radiography | 2 | 2010 | 505 | 0.040 |
Why?
|
| Eosinophils | 1 | 2017 | 51 | 0.040 |
Why?
|
| Bronchodilator Agents | 1 | 2018 | 97 | 0.040 |
Why?
|
| Algorithms | 2 | 2013 | 981 | 0.040 |
Why?
|
| Health Surveys | 1 | 2018 | 306 | 0.030 |
Why?
|
| Walk Test | 1 | 2016 | 7 | 0.030 |
Why?
|
| Serpin E2 | 2 | 2006 | 2 | 0.030 |
Why?
|
| Protease Nexins | 2 | 2006 | 3 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2016 | 131 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2020 | 477 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2023 | 1013 | 0.030 |
Why?
|
| Lod Score | 2 | 2005 | 26 | 0.030 |
Why?
|
| Phospholipases A2, Secretory | 1 | 2015 | 1 | 0.030 |
Why?
|
| Thiobarbituric Acid Reactive Substances | 1 | 2015 | 16 | 0.030 |
Why?
|
| Mucin 5AC | 1 | 2015 | 7 | 0.030 |
Why?
|
| Airway Remodeling | 1 | 2015 | 7 | 0.030 |
Why?
|
| Incidence | 1 | 2018 | 1226 | 0.030 |
Why?
|
| Fatigue | 2 | 2009 | 103 | 0.030 |
Why?
|
| Gene Knock-In Techniques | 1 | 2015 | 34 | 0.030 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2015 | 25 | 0.030 |
Why?
|
| Pulmonary Alveoli | 1 | 2015 | 43 | 0.030 |
Why?
|
| Macaca fascicularis | 1 | 2014 | 47 | 0.030 |
Why?
|
| Cause of Death | 1 | 2016 | 200 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2015 | 254 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2015 | 147 | 0.030 |
Why?
|
| Age Distribution | 1 | 2015 | 261 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2015 | 249 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2015 | 105 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2018 | 444 | 0.030 |
Why?
|
| Unrelated Donors | 1 | 2014 | 6 | 0.030 |
Why?
|
| Antilymphocyte Serum | 1 | 2014 | 21 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2014 | 128 | 0.030 |
Why?
|
| Anthropometry | 1 | 2014 | 79 | 0.030 |
Why?
|
| Allografts | 1 | 2014 | 44 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2005 | 291 | 0.030 |
Why?
|
| Pulmonary Medicine | 1 | 2014 | 25 | 0.030 |
Why?
|
| Leukocytes | 1 | 2014 | 107 | 0.030 |
Why?
|
| Demography | 1 | 2014 | 178 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2015 | 297 | 0.030 |
Why?
|
| Child | 1 | 2022 | 4239 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2014 | 307 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2016 | 830 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2014 | 291 | 0.030 |
Why?
|
| Florida | 1 | 2011 | 40 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 1516 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 701 | 0.020 |
Why?
|
| Registries | 1 | 2015 | 799 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2011 | 98 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2015 | 1981 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 576 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2014 | 956 | 0.020 |
Why?
|
| Leukocytosis | 1 | 2009 | 12 | 0.020 |
Why?
|
| Fever | 1 | 2009 | 63 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 1090 | 0.020 |
Why?
|
| Residual Volume | 1 | 2007 | 3 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 197 | 0.020 |
Why?
|
| Haplotypes | 1 | 2005 | 117 | 0.020 |
Why?
|
| Inspiratory Capacity | 1 | 2004 | 1 | 0.020 |
Why?
|
| Total Lung Capacity | 1 | 2004 | 9 | 0.020 |
Why?
|
| Chromosomes, Human | 1 | 2004 | 53 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 846 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2005 | 458 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 522 | 0.010 |
Why?
|
| Muscular Diseases | 1 | 2003 | 45 | 0.010 |
Why?
|
| Maximal Midexpiratory Flow Rate | 1 | 2002 | 2 | 0.010 |
Why?
|
| Nutritional Status | 1 | 2003 | 118 | 0.010 |
Why?
|
| Sickness Impact Profile | 1 | 2002 | 46 | 0.010 |
Why?
|
| Muscle Contraction | 1 | 2003 | 198 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2002 | 327 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2004 | 1460 | 0.010 |
Why?
|